5-Fluorouracil (5-FU) — chemotherapy in gastrointestinal and other cancers

What 5-FU is in simple patient language

5-Fluorouracil — 5-FU for short. It has been in oncology for decades. That is not a reason to dismiss it. It stays in active use because certain tumor types respond to it and it slots into combinations that have a long track record.

Patients rarely encounter it as a standalone drug. It tends to appear as part of something bigger — FOLFOX, FOLFIRI, FOLFIRINOX, or running alongside radiation in rectal cancer treatment. The regimen name tells most of the story. The 5-FU inside it is one component.

It goes in through a drip. Some protocols use a short infusion in the clinic. Others run it through a pump the patient takes home, delivering the drug slowly over two days. Both are 5-FU. The experience of treatment is different. That distinction should be explained before the first cycle, not discovered at the end of the first appointment.

How 5-FU works

To copy their DNA, dividing cells need specific building blocks. 5-FU mimics one of those building blocks closely enough to get taken up — then blocks the enzyme that needs it. Copying stalls. The cell cannot divide properly and eventually stops.

It hits fast-dividing cells hardest. That is the tumor. It is also the gut lining, mouth, and bone marrow. Those tissues replace themselves constantly, which is why mouth sores, diarrhea and blood count drops show up as side effects — not a malfunction, just the drug reaching tissue it was not meant to spare.

How it is given changes which effects dominate. A fast bolus infusion and a slow continuous infusion deliver the same molecule through a different pharmacological window. The toxicity pattern shifts. Mouth sores and diarrhea are more prominent with continuous infusion. The oncologist chooses the schedule for a reason, and understanding that reason is part of being prepared.

Which conditions may be treated with 5-FU

5-FU turns up across several cancer types, most of them gastrointestinal.

• colon and rectal cancer — adjuvant after surgery and in metastatic disease
• rectal cancer combined with radiation before surgery
• gastric and gastroesophageal junction cancer
• pancreatic cancer as part of FOLFIRINOX
• anal canal cancer combined with mitomycin and radiation
• head and neck cancer in certain protocols
• breast cancer in selected combination regimens

Diagnosis is a starting point. Stage, molecular profile, treatment goal, previous lines and physical condition all shape whether 5-FU belongs right now and in which form.

When 5-FU can be especially relevant

A few situations put it naturally into the conversation.

• colorectal cancer where FOLFOX, FOLFIRI or something similar is on the table
• rectal cancer where chemotherapy and radiation run together before surgery
• adjuvant treatment after gastrointestinal tumor resection
• gastric or pancreatic cancer where a fluoropyrimidine fits the regimen
• oncologist comparing infusional 5-FU against capecitabine tablets
• second opinion on which regimen matches the clinical situation

5-FU and capecitabine get discussed together often. They are related but not the same thing. Which one fits depends on the regimen structure, the tumor type and whether the patient can manage a reliable tablet schedule. One is not automatically a substitute for the other — that comparison needs to happen explicitly.

What should be checked before treatment

Before the first infusion the team needs more than the diagnosis and the regimen name.

• tumor type, stage and treatment goal
• previous chemotherapy and how it was tolerated
• full blood count
• kidney and liver function
• DPD enzyme status — patients with low DPD activity cannot clear fluoropyrimidines normally and face severe toxicity at standard doses
• existing mouth sores or gastrointestinal problems
• cardiac history — 5-FU can cause coronary spasm in a small number of patients
• current medications
• whether a pump will be used and whether the patient can manage it at home

DPD testing deserves specific attention. A patient with reduced DPD activity given a standard dose of 5-FU can develop severe and life-threatening toxicity. Testing is not universal in all countries but where available it should be discussed. Even without testing, knowing the warning signs — early severe diarrhea, mouth sores, sudden deterioration within the first days — matters.

How treatment with 5-FU is usually given

Two main formats exist. A short infusion given in the clinic as part of a cycle. Or a prolonged infusion delivered through a portable pump, usually over 46 hours, then disconnected at the clinic or sometimes by the patient at home.

Pump patients go home with treatment still running. Before that happens they need to know how the pump works, what a blockage or leak looks like, who to call and when to go in. This is not information to absorb on the day of the first infusion.

During treatment the team monitors:

• full blood count before each cycle
• mouth — soreness, ulcers, difficulty eating or drinking
• stool frequency and consistency
• weight and signs of dehydration
• cardiac symptoms — chest tightness or pain during or after infusion
• skin and hand-foot reactions with prolonged infusion schedules
• liver function
• imaging at planned intervals to assess response

Cardiac symptoms during or after 5-FU are uncommon but they are the one side effect that needs immediate attention rather than a call at the next convenient moment. Chest tightness or pressure during an infusion means stopping the drip and contacting the team straight away.

Possible side effects

5-FU’s side effect profile depends partly on how it is given.

• mouth sores — can become severe enough to prevent eating or drinking
• diarrhea — sometimes significant, risk of dehydration
• nausea and reduced appetite
• marrow suppression — neutrophils and platelets can fall
• fatigue
• hand-foot syndrome with prolonged infusion — redness, soreness and peeling on palms and soles
• cardiac spasm — rare but requires immediate response
• hair thinning — less pronounced than with taxanes
• taste changes

DPD deficiency changes everything. Without enough of that enzyme, 5-FU accumulates rather than clearing normally. The result is severe toxicity arriving fast — heavy diarrhea, deep mouth ulcers, significant marrow suppression within the first few days of treatment. That pattern is a signal. The team needs to hear about it immediately, not at the next planned visit.

When to contact a doctor urgently

Some symptoms cannot wait for a scheduled appointment.

• fever or chills — call the same day, every time
• mouth sores so severe that swallowing liquids becomes painful or impossible
• diarrhea four or more times in one day, or diarrhea accompanied by significant weakness
• chest tightness or pain during or after infusion — if a pump is running, disconnect it and call immediately
• unusual bleeding or bruising
• severe hand or foot pain, blistering or open skin
• repeated vomiting preventing fluids
• any sudden or unexplained drop in general condition

Mouth sores that stop a patient from drinking lead to dehydration faster than most people expect. This is not a symptom to push through until the next scheduled visit. The team needs to know early enough to help.

Why 5-FU is not right for every patient

Widely used does not mean universally safe. Several factors can make 5-FU the wrong choice or require significant adjustment.

• confirmed or suspected DPD deficiency
• significant cardiac history — coronary disease increases the risk of coronary spasm
• severe existing mouth or gut problems
• very low blood counts before treatment
• poor general condition where the regimen’s demands are unsafe
• situations where capecitabine is a better fit for the combination and the patient

Capecitabine converts to 5-FU inside the body. For some patients and some regimens it is the more practical choice. For others, infusional 5-FU is specifically what the protocol requires. The comparison is worth having explicitly rather than assuming one is simply a convenient substitute for the other.

Can 5-FU be combined with other treatments

Almost always yes. 5-FU rarely runs alone in current practice. Common combinations:

• leucovorin — given alongside 5-FU to enhance its effect, part of most FOLFOX and FOLFIRI schedules
• oxaliplatin — FOLFOX, used across colorectal and gastric cancer
• irinotecan — FOLFIRI, an alternative backbone for colorectal cancer
• oxaliplatin and irinotecan together — FOLFIRINOX, primarily in pancreatic cancer
• mitomycin and radiation in anal canal cancer
• radiation therapy in rectal cancer before surgery
• targeted agents where the molecular profile supports adding them

What 5-FU is paired with shapes the treatment experience significantly. FOLFOX brings neuropathy from oxaliplatin. FOLFIRI brings diarrhea from irinotecan. FOLFIRINOX is the most intensive of the three. The regimen name matters — not just the 5-FU component inside it.

What no quick response can mean

Response is not measured after the first cycle. Imaging, markers and clinical assessment after several cycles give the picture. One scan or one PSA is rarely enough to draw conclusions either way.

If disease is clearly progressing, if toxicity is becoming unsafe, or if the original treatment goal no longer fits — the plan needs reviewing. 5-FU is one component of a strategy. When the strategy needs updating, that conversation should not be delayed.

Oncology consultation in Israel

Tel Aviv Medical Clinic offers oncology consultations and second opinions for patients on a 5-FU-based regimen or trying to understand which regimen fits their situation.

The consultation can cover:

• pathology, molecular profile and imaging review
• treatment history and response to prior lines
• DPD status and its implications for dosing
• comparison of regimens — FOLFOX, FOLFIRI, FOLFIRINOX and others
• 5-FU versus capecitabine — when one fits better than the other
• second opinion on the current or proposed plan
• questions to bring back to the treating oncologist

We do not replace the treating doctor. We help the patient arrive at the next conversation with a clear picture of the options.

Frequently asked questions — answered by Dr. Stefanska and Dr. Meerovich

1. What is the difference between 5-FU and capecitabine?

Capecitabine is a tablet. Once swallowed, the body converts it into 5-FU. The active molecule ends up being similar. The practical experience is completely different — one means a pump or clinic infusion, the other means tablets at home twice a day. Which one fits depends on the regimen, the tumor type, whether the protocol specifically requires infusional delivery, and whether the patient can manage a consistent oral schedule. Neither is automatically a substitute for the other — that choice should be explained rather than assumed.

2. What is DPD and why does it matter?

DPD is an enzyme that breaks down fluoropyrimidines including 5-FU. Patients with reduced DPD activity cannot clear the drug at a normal rate. At a standard dose, the drug accumulates and causes severe toxicity — significant diarrhea, deep mouth ulcers, serious marrow suppression — appearing within the first days. Testing before treatment identifies patients at risk. Where testing is available, it is worth discussing. Where it is not, knowing the warning signs matters even more.

3. What should I do if I go home with a pump?

Understand it before you leave the clinic. Know what it looks like when it is running normally, what a blockage or disconnection looks like, what the alarm means, and who to call at any hour. If chest tightness or pain develops while the pump is running, disconnect it if you know how and call the team immediately — do not wait to see if it passes. A pump running at home means the team needs to be reachable and the patient needs to know how.

4. How serious are mouth sores with 5-FU?

They range from mild discomfort to severe ulceration that makes eating or drinking painful or impossible. Severe mouth sores lead to dehydration faster than most patients expect. The team needs to know when mouth sores reach the point where drinking becomes difficult — not at the next scheduled visit, but at that point. Early intervention keeps a manageable problem from becoming a reason to stop treatment.

5. What documents should I bring for a second opinion?

Pathology with molecular profile if available, recent imaging, the full treatment history with dates, the current regimen and schedule, recent bloods. If DPD testing has been done, bring those results. If there have been significant side effects — early severe diarrhea, mouth problems, cardiac symptoms — write down when they happened and how severe they were. That specific account is what makes a second opinion useful.

Important information

This page gives general medical information. It is not a personal treatment plan. 5-FU should be discussed only after review of the diagnosis, stage, DPD status, cardiac history, previous treatment and the patient’s overall condition.

Do not start, stop or change chemotherapy without your treating oncologist.

For consultation about 5-FU treatment:

📞 +972-73-374-6844

📧 [email protected]

💬 WhatsApp: +972-52-337-3108